<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Blinatumomab and EBV reactivation &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/blinatumomab-and-ebv-reactivation/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Jan 2026 03:33:10 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Blinatumomab and EBV reactivation &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Blinatumomab Boosts Epstein-Barr Virus Reactivation Pre-Transplant</title>
		<link>https://bioengineer.org/blinatumomab-boosts-epstein-barr-virus-reactivation-pre-transplant/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 24 Jan 2026 03:32:44 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Allojenik kök hücre nakli]]></category>
		<category><![CDATA[Blinatumomab and EBV reactivation]]></category>
		<category><![CDATA[Epstein-Barr virüsü]]></category>
		<category><![CDATA[Hematolojik maligniteler** **Açıklama:** 1. **Blinatumomab:** Makalenin ana konusu ve araştırmanın odağı olan ilacın adı. En önemli anahtar kelime. 2]]></category>
		<category><![CDATA[Hematopoietic stem cell transplantation complications]]></category>
		<category><![CDATA[Immunotherapy adverse effects]]></category>
		<category><![CDATA[İşte 5 uygun etiket: **Blinatumomab]]></category>
		<category><![CDATA[Pre-transplant immunotherapy risks]]></category>
		<category><![CDATA[Viral reactivation in oncology]]></category>
		<category><![CDATA[Viral reaktivasyon]]></category>
		<guid isPermaLink="false">https://bioengineer.org/blinatumomab-boosts-epstein-barr-virus-reactivation-pre-transplant/</guid>

					<description><![CDATA[Recent research has unveiled a critical relationship between the administration of Blinatumomab and the reactivation of Epstein-Barr virus (EBV) in patients undergoing allogeneic stem cell transplantation. This revelation comes in the wake of growing concerns about the management of viral reactivations during immunosuppressive therapies, particularly in oncology, where maintaining a delicate balance between eradicating malignancies [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320136</post-id>	</item>
	</channel>
</rss>
